Bortezomib Injection, Powder, Lyophilized, For Solution
Product Images NDC 25021-262

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Bortezomib (NDC 25021-262). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Bor06 0000 01)

Chemical structure of BORTEZOMIB showing its molecular framework, including boron, nitrogen, oxygen, and carbon atoms arranged as depicted.*

FDA Label Image

Figure 1 (Bor06 0000 02)

A Kaplan-Meier survival curve chart showing the percentage of patients over time in months. It compares two treatment groups labeled Vc-MP and MP, with patient counts displayed below the x-axis at various time points. The chart includes a p-value indicating statistical significance.*

FDA Label Image

Figure 2 (Bor06 0000 03)

A Kaplan-Meier survival curve showing the percentage of patients over time (months) for two treatment groups labeled Vc-MP and MP. The graph includes a p-value indicator (< 0.05) and a table below showing the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 3 (Bor06 0000 04)

A Kaplan-Meier survival curve comparing the proportion of patients over time (in days) treated with Bortezomib versus Dexamethasone. The graph shows a higher survival proportion for Bortezomib across the timeline with statistical significance noted (p < 0.0001). The x-axis represents time in days, and the y-axis represents the proportion of patients remaining at risk.*

FDA Label Image

Figure 4 (Bor06 0000 05)

A survival curve graph comparing the proportion of patients over time (days) between Bortezomib and Dexamethasone treatments. The graph shows two lines, one for Bortezomib in blue and one for Dexamethasone in red, with patient counts at various time points indicated below the x-axis. A p-value from a log-rank test (<0.05) is noted, highlighting statistical comparison between the groups.*

FDA Label Image

Figure 5 (Bor06 0000 06)

A Kaplan-Meier survival curve comparing two treatment groups, VcR-CAP and R-CHOP, showing percentage of patients over time in months. The chart includes a log-rank test p-value (<0.001) and a table of subjects at risk at various time points for both groups.*

FDA Label Image

Figure 6 (Bor06 0000 07)

A Kaplan-Meier survival curve depicting percentage of subjects alive over months from randomization for two treatment groups, VcR-CAP (solid line) and R-CHOP (dashed line). The chart includes hazard ratio with 95% confidence interval and a table showing subjects at risk at various time points for each group.*

FDA Label Image

Package Label – Principal Display Panel – Vial Label (Bor06 0000 08)

BORTEZOMIB for Injection 3.5 mg per vial single-dose vial label. The label indicates the product is sterile, nonpyrogenic, preservative-free, and lyophilized for intravenous or subcutaneous use. It includes a caution that it is a cytotoxic agent and storage instructions between 15 to 30°C. Manufactured by Sagent Pharmaceuticals, Schaumburg, IL, with the vial containing 3.5 mg of bortezomib.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.